Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/2020

01-03-2020 | Breast Cancer | Retraction Note

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells

Authors: Zhaoliang Su, Ping Ni, Peng She, Yueqin Liu, Seidu A. Richard, Wenlin Xu, Haitao Zhu, Jia Wang

Published in: Cancer Immunology, Immunotherapy | Issue 3/2020

Login to get access

Excerpt

The Editor-in-Chief has retracted this article [1] because a number of the images in Fig. 4a and c, appear to have been duplicated then either rotated, cropped or stretched to make them appear to be different tumors. The Editor-in-Chief no longer has confidence in the results and conclusions presented in this article. Jia Wang agrees with this retraction. Seidu A. Richard does not agree with this retraction. Zhaoliang Su, Ping Ni, Peng She, Yueqin Liu, Wenlin Xu and Haitao Zhu have not responded to correspondence about this retraction. …
Literature
1.
Metadata
Title
Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells
Authors
Zhaoliang Su
Ping Ni
Peng She
Yueqin Liu
Seidu A. Richard
Wenlin Xu
Haitao Zhu
Jia Wang
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 3/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02489-9

Other articles of this Issue 3/2020

Cancer Immunology, Immunotherapy 3/2020 Go to the issue

Original Article

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

Clinical Trial Report

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Original Article

Immune checkpoint inhibitors combined with chemotherapy for the treatment of advanced pancreatic cancer patients

Original Article

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

Original Article

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study

Review

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits